San Diego Startup Goes After Elusive Drugs With Expanded DNA Alphabet
Synthorx's CEO Court Turner speaks with Stat about the company's new technology.
A Biotech Startup Is Expanding The DNA Alphabet In Hopes Of Making Novel Drugs
San Diego synthetic biology company Synthorx is entering the drug discovery game with a couple extra base pairs up its sleeve: It’s developing new biologic drugs with an expanded DNA alphabet, adding synthetic nucleotides X and Y to the standard lineup of A, C, G, and T. The company just raised $10 million, on top of $6 million in investment it collected back in 2014. CEO Court Turner spoke with STAT about the company’s technology — and its plans for developing drugs for diabetes and other conditions with that loaded-up DNA. (Keshavan, 7/20)